Cohort details
| Patient No./Age (y)/Sex | EDSS | ΔY1 | ΔY2 | WBNAA Concentration (mM) | Group* | Medications |
|---|---|---|---|---|---|---|
| 1/27.6/F | 2.5 | 0.53 | 2.78 | 7.14 | R | Avonex |
| 2/28.1/F | 1 | 0.26 | 1.68 | 14.52 | S | Copaxone |
| 3/29.8/F | 0 | 3.32 | 3.83 | 12.87 | M | Avonex |
| 4/31.3/F | 1.5 | 8.19 | 8.94 | 9.96 | M | Avonex |
| 5/33.1/M | 1 | 2.7 | 3.2 | 12.69 | M | Avonex |
| 6/34.5/F | 1.5 | 6.47 | 6.47 | 13.87 | S | Avonex |
| 7/34.7/F | 2 | 0.15 | 3.62 | 9.65 | R/M† | Copaxone |
| 8/37.2/F | 3 | 2.55 | 2.72 | 7.85 | R | Avonex |
| 9/37.9/F | 3 | 0.32 | 0.32 | 9.37 | R | N/A |
| 10/38.4/M | 1.5 | 0.95 | 18.29 | 13.55 | S | Avonex |
| 11/41.5/F | 2 | 0.65 | 1.07 | 10.91 | R | Avonex |
| 12/42.8/F | 1 | 1.16 | 1.24 | 13.9 | S | Avonex |
| 13/44.3/F | 2 | 7.37 | 7.53 | 10.28 | M | N/A |
| 14/45.1/M | 0 | 3.05 | 11.06 | 10.98 | M | N/A |
| 15/45.7/M | 2.5 | 2.24 | 2.24 | 10.82 | M | Avonex |
| 16/54.9/F | 6 | 2.3 | 4.55 | 16.01 | S | Bestaseron |
| Average | 2.1 | 2.64 | 4.97 | 11.39 ± 2.5 |
Note:—EDSS indicates Expanded Disability Status Scale; Δ Y1, disease duration since clinically definite diagnosis (years); Δ Y2, disease duration from first clinical event (years); WBNAA, whole-brain N-acetylaspartate. The average age of patients studied was 37.9 ± 7.7.
* Subgroup notations are S, stable; M, moderate; R, rapid.
† Assignment changed from rapid (based on Δ Y1) to moderate when estimated from Δ Y2 disease duration.